氨酸脱甲基酶LSD1与EBV阳性B细胞淋巴瘤的干性相关
Joo Hyun Kim1, Chaehwa Park2, Won Seog Kim3,4
1Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, 06351, Korea.
Scientific reports
|March 22, 2024
概括
艾普斯坦-巴尔病毒 (EBV) 阳性淋巴瘤的治疗方法正在改善. 像TCP这样的LSD1抑制剂,在与多克索鲁比结合时,通过减少癌症干的承诺,提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 病毒学 病毒学
背景情况:
- 艾普斯坦-巴尔病毒 (EBV) 感染的淋巴瘤具有严重的临床挑战,预后不佳.
- 表观遗传失调与B细胞淋巴瘤的发展有关,突出了潜在的治疗点.
- 向表观遗传机制为治疗EBV阳性淋巴瘤提供了一种新的策略.
研究的目的:
- 在EBV阳性淋巴瘤中识别与多克索鲁比辛协同作用的表观遗传药物.
- 研究氨酸特异性脱甲酶1 (LSD1) 在EBV诱导的淋巴瘤干的作用.
主要方法:
- 在表达EBV的LMP1蛋白的B细胞淋巴瘤细胞系中选100种表观遗传修饰剂,与多克索鲁比结合使用.
- 包括殖民地形成和ALDEFLUOR在内的测试以评估茎状性.
- 量子3'mRNA测序用于识别LSD1受调节的基因.
主要成果:
- 一种LSD1抑制剂TCP与多克索鲁比产生了协同效应.
- LMP1 增强了 LSD1 的活性,在多克索鲁比辛治疗下促进了癌症干细胞的生长.
- LSD1抑制降低了LMP1诱导的CHAC2上调,并影响了SOX2表达,影响了茎状.
结论:
- LSD1抑制剂代表了EBV阳性淋巴瘤的有希望的治疗候选者.
- 将LSD1抑制剂与常规化疗相结合可能会降低癌症的发育率并提高治疗效率.
相关概念视频
01:21Lineage Commitment
3.0K
Commitment is the process whereby stem cells:
3.0K
03:18Non-LTR Retrotransposons
11.5K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.5K
01:06Multipotency and Niche of Bulge Stem Cell
3.6K
A hair follicle or HF is a small part of the skin that produces the hair shaft. Paul Gerson Unna was the first to observe a bulge in the human hair follicle's outer root sheath (ORS). The bulge is present between the sebaceous gland and the arrector pili muscle and is the niche for hair follicle stem cells (HFSCs). The bulge is also a niche for melanocyte stem cells, and their loss results in graying of hair. The HFSCs express Sox9 and Lhx2, which help them maintain stemness and prevent...
3.6K
01:32Chromatin Modification in iPS Cells
1.6K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
1.6K
01:19Multipotency of Hematopoietic Stem Cells
3.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K
01:14Maintenance of the ES Cell State
2.2K
The cells of the blastocyst inner cell mass only remain pluripotent for a short time. This state of pluripotency and self-renewal can be maintained in embryonic stem (ES) cell culture by adding specific chemicals or growth factors to ensure the cells can continue dividing and later differentiate into different cell types. In some cases, the cells are grown on a feeder layer of differentiated cells, which provides the growth factors and extracellular matrix components necessary for stem cell...
2.2K